神经胶质瘤中β-抑制蛋白1的表达及意义

目的检测神经胶质瘤中β-抑制蛋白1(ARRB1)的表达水平及临床意义。方法采用RT-PCR和Western blotting检测胶质瘤细胞系中ARRB1的表达水平;通过肿瘤微阵列数据库(Oncomine)及Project Betastasis平台分析ARRB1 mRNA在神经胶质瘤中的表达情况;采用免疫组织化学方法检测神经胶质瘤组织及瘤旁脑组织中ARRB1的表达水平;应用Kaplan Meier分析ARRB1的表达水平与胶质瘤患者预后的关系。结果与正常人脑组织和人胚肾细胞系(HEK293)相比,神经胶质瘤细胞系中ARRB1的mRNA和蛋白水平降低;Oncomine数据库结果显示,多个神经胶质瘤基因芯片中ARRB1 mRNA水平较正常对照组明显降低(P0.001),ARRB1在恶性程度较高的胶质母细胞瘤中下降程度更加明显;免疫组织化学结果显示,与瘤旁脑组织相比神经胶质瘤中ARRB1表达降低,而且Ⅲ-Ⅳ期较Ⅰ-Ⅱ期神经胶质瘤降低更加明显。此外,Kaplan-Meier生存曲线结果显示,ARRB1的表达水平与神经胶质瘤患者的生存时间存在相关性(P0.05)。结论神经胶质瘤ARRB1水平下调,可作为反映神经胶质瘤临床病理学特点的指标;另外,ARRB1可作为判断神经胶质瘤患者预后的生物标志物。

Expression and significance of arrestin beta 1 in patients with glioma

Objective To detect the expression levels of arrestin beta 1 (ARRB1) in patients with glioma, and assess its clinical significance. Methods The expression levels of ARRB1 in glioma cell lines were detected by RT-PCR and Western blot; ARRB1 mRNA expression in glioma was analyzed from Oncomine database and Project Betastasis platform; the expression of ARRB1 in glioma and peritumoral brain tissue was detected by immunohistochemistry; the association of ARRB1 expression levels with the prognosis of patients was analyzed by Kaplan Meier method. Results Compared with normal brain tissue and cell line HEK293, the mRNA and protein levels of ARRB1 in glioma cell lines were reduced; Oncomine database showed ARRB1 mRNA levels in multiple glioma microarray were significantly lower than the normal control group (P<0.001), specially in highly malignant glioblastoma. Immunohistochemistry data showed that ARRB1 expression in glioma tissues was reduced compared with the peritumoral brain tissue, and the expression of ARRB1 in Ⅲ-Ⅳ stage of gliomas was reduced more significantly than that in stage Ⅰ-Ⅱ glioma. In addition, Kaplan-Meier survival curves showed that the expression level of ARRB1 in glioma was correlated with patients survival (P<0.05). Conclusion Reduced ARRB1 expression level in glioma could be used to evaluate the clinical and pathological features of glioma, and the ARRB1 can be used a biomarker to judge the prognosis of patients with glioma.